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Several female malignancies including breast, ovarian, and endometrial cancers can be characterized based on known somatic
and germline mutations. Initiation and propagation of tumors reﬂect underlying genomic alterations such as mutations,
polymorphisms, and copy number variations found in genes of multiple cellular pathways. The contributions of any single genetic
variation or mutation in a population depend on its frequency and penetrance as well as tissue-speciﬁc functionality. Genome
wide association studies, ﬂuorescence in situ hybridization, comparative genomic hybridization, and candidate gene studies have
enumerated genetic contributors to cancers in women. These include p53, BRCA1, BRCA2, STK11, PTEN, CHEK2, ATM, BRIP1,
PALB2, FGFR2, TGFB1, MDM2, MDM4 as well as several other chromosomal loci. Based on the heterogeneity within a speciﬁc
tumor type, a combination of genomic alterations deﬁnes the cancer subtype, biologic behavior, and in some cases, response to
therapeutics. Consideration of tumor heterogeneity is therefore important in the critical analysis of gene associations in cancer.
1. InheritedMutationsthat Predisposeto
Cancers in Women
There is strong evidence that inherited genetic factors
(mutations plus single nucleotide polymorphisms) can play
a major role in breast cancer susceptibility [1]. Inherited
mutations in a small number of genes account for about
ﬁve to ten percent of women’s cancers. These inherited
variations, identiﬁed in breast, ovarian, and endometrial
cancer susceptibility, can be characterized in the general
population by their frequency and the magnitude of their
impact upon a patient (Table 1). Some inherited variants
occur rarely in the general population, but confer large risks
to the individual. Examples of these genes are BRCA1 and
BRCA2 in breast and ovarian cancers. A second class of
inherited variants confers a lower risk, and these variants are
also rare in the general population. An example of this class
of genes is a mutation in the CHEK2 gene in breast cancer.
The third class, composed of high-risk variants that are also
common in the population, has never been identiﬁed by the
methodspresentlyavailableandmayinfactnotexistbecause
it may well be strongly selected against in populations.
Finally, a fourth class of inherited variants includes those
that confer low disease risk to the individual, but occur at
higher frequencies in populations. These include some of
the recent ﬁndings from genome-wide association studies
(GWASs) mostly with breast cancers. A summary of the
major ﬁndings to date for these genes is in Table 1 and is
discussed in what follows.
Despite these advances made in identifying inherited
breast cancer susceptibility genes, the vast majority of breast
cancers are sporadic, that is, no identiﬁable mutation in one
of the known breast cancer susceptibility genes. While this
may reﬂect the fact that we have yet to identify the next
BRCA gene, it may also reﬂect the polygenic nature of breast
cancer susceptibility. Other contributors to genetic suscep-
tibility, for example, polymorphisms, may have a higher
relative contribution to risk, but their lower penetrance
makes identiﬁcation more diﬃcult. Furthermore, modiﬁ-
cation of genetic susceptibility by environmental factors,2 Journal of Oncology
Table 1: Genetic loci implicated in hereditary, familial, and
sporadic breast cancer susceptibility.
High penetrance, Low penetrance, Low penetrance,
low frequency low frequency High frequency
BRCA1 CHEK2 FGFR2
BRCA2 ATM LSP1
PTEN PALB2 MAP3K1
p53 BRIP1 TGFB1
STK11 TOX3
2q35
8q
both endogenous and exogenous, may alter the degree of
penetrance. Supporters of the polygenic nature of breast
cancer suggest that the contributions from polymorphisms
are very important because of their high frequency in the
population.
1.1. High-Penetrance, Low-Frequency Inherited Variants.
Although inherited mutations in a small number of genes
account for only about ﬁve to ten percent of women’s
cancers, by far the BRCA1 and BRCA2 gene mutations are
the most common examples of this observation (50–70% of
familial breast cancers) [2]. In some populations BRCA1 and
BRCA2 mutations can account for ten percent of all breast
cancers (Ashkenazi Jewish populations) and ovarian cancers
but in many ethnic groups and in all populations taken
together these mutations are much rarer (reviewed in [3]).
The BRCA1 and BRCA2 proteins appear to be scaﬀolding
proteins that assemble DNA repair complexes of proteins
at double-strand DNA breaks (mediating homologous DNA
repair processes) (reviewed in [4]). Mutations in these
genes result in a faulty repair process and a high mutation
rate, especially during DNA replication, leading to cancers.
The penetrance of these mutations for cancer occurrence
and the age of onset of these cancers in women can be
quite variable. There have been a number of other possible
functions ascribed to the BRCA1 and BRCA2 proteins such
as ubiquitin ligase activity and a modiﬁer of transcription
and it is certainly possible that these protein complexes
act in several ways [5]. Breast cancers initiated in women
who are heterozygous for BRCA1 or BRCA2 often have a
reduction to homozygosity at the BRCA-locus eliminating
its functions. This results in DNA damage in the tumor
which should activate the p53 protein resulting in apoptosis,
senescence, or cell cycle arrest. If this is the case, the p53
geneproductwouldbeasuppressorofthiscancerphenotype
and contribute to the variable penetrance of these breast
cancer genes. Consistent with this is the observation that
BRCA1/2-initiated breast cancers have very high rates (29–
84%) of somatic p53 mutations compared to 14–35% in
non-BRCA1/2-related breast cancer [6].
Inherited mutations in several other genes, such as PTEN
andp53,cangiverisetocancersinwomen.Cowden’sDisease
is a heterozygous deﬁciency in the PTEN gene that can
result in breast, endometrial, and other cancers [3, 7]. The
PTEN protein is a lipid (PIP-3) phosphatase that modulates
a growth factor pathway, in turn regulating metabolic
pathways in cells, angiogenesis, mitochondrial functions and
apoptotic functions [8]. Genetic alterations in this pathway
are among the most common somatic mutations observed in
breast and endometrial cancers [9, 10]. Mutations in LKB1
also predispose to breast and ovarian cancers as one of the
phenotypes in Peutz-Jeghers syndrome [3, 11]. Inherited
defects in one allele of the p53 gene give rise to Li-Fraumeni
syndrome, where a subset of the cancers observed at an early
age are breast cancers [12].
1.2. Low-Penetrance, Low-Frequency Inherited Variants. This
class of inherited variants is diﬃcult to detect with existing
methods because the rarity of these variants and coupled
with small eﬀect sizes this means that most association
studies will not be able to detect them due to limitations in
population sizes under study. In the extreme, these variants
may represent “private” mutations that confer a small degree
of risk to very few individuals in this population, such that
nearly every person would have a unique set of predisposing
alleles. While it has been diﬃcult to detect inherited variants
of this type there are several examples of this type of variant
which were uncovered by examining candidate genes that an
investigator suspected played a role in a cancer. Inherited
alterations in the CHEK2 gene which normally produces
a protein kinase found in signal transduction pathways
(p53 pathway and others), alerts the cell that there is DNA
damage and its loss can have an impact upon several types
of cancer [13]. Similarly the ATM protein kinase harbors
genetic variants that detect single- and double-strand breaks
in the DNA and signals to the p53 pathway and other DNA
repair processes. Variants in this gene could lower or raise
thesensitivityofthisDNAdamagedetectorandimpactupon
the eﬃciency of p53 and its tumor suppressor pathway and
c a np r e d i s p o s ew o m e nt ob r e a s tc a n c e r s[ 14]. The BRIP1
gene (BRCA1 interacting protein-1) encodes a protein that
is a DNA/RNA helicase of the REC Q family that binds
to the carboxy-terminus of BRCA1 protein conferring an
activity involved in DNA repair and variants of this gene
can predispose to breast cancers [15]. Interestingly this gene
product is also a component of the Fanconi anemia gene
pathway for DNA repair processes. Finally the PALB2 gene
product (partner and localizer of BRCA2) is part of the
BRCA2 protein complex and plays a role in DNA repair.
It has recently been shown to be a genetic determinant of
familial breast and other cancers primarily in the certain
populations, but found at even lower frequency in other
populations [16].
1.3. Low-Penetrance, High-Frequency Inherited Variants.
Fewer than 10% of breast cancers are attributable to known
mutations in breast cancer susceptibility genes BRCA1 and
BRCA2. The multigenic susceptibility due to common, low-
penetrance risk markers is yet to be deﬁned [1, 17–20].
Both candidate gene [21] and genome-wide association
studies have identiﬁed novel markers for susceptibility [22–
25] and prognosis [26]. Genome-wide association studiesJournal of Oncology 3
have become widely used to identify commonly occurring
alleles at disease susceptibility loci. These studies use a large
number of high-density markers to identify associations
with disease that rely upon patterns of linkage disequilib-
rium in the human genome. GWASs have been successful
in identifying genes for breast cancer, and GWASs for
ovarian and endometrial cancers are underway although
several investigators have validated ﬁndings from GWAS
studies designed originally for breast cancer studies but
employed for ovarian cancer [27]. Some of the more
reproducible genes that GWASs studies have indicated can
play a role in the risk for developing breast cancers include
FGFR2, LSP1, MAP3K1, TGFB1, TOX3, 2q35, and 8q
[17, 22, 24].
2. Somatic MutationsThat AreCommonly
ObservedinWomen’sCancers
Both gene ampliﬁcations and deletions can lead to common
somatic mutations in women’s cancers. Among the ampliﬁ-
cations are the following. (1) HER-2/Neu, ampliﬁed in about
15% of the breast cancers, is a growth receptor that activates
the Ras-MEK and the PI3K pathways in cancer cells [28]. (2)
Cyclin D, ampliﬁed in about 10–12% of the breast cancers,
is a subunit of the cyclin dependent kinase −4/6 that acts
upon the Rb protein freeing the E2F transcription factor for
entryintothecellcycle[28,29].(3)WIP1,ampliﬁedinabout
13% of breast cancers, is a serine/threonine phosphatase
that inactivates the ATM kinase and the p53 protein [30].
The GASC1 gene, which produces a histone demethylase
activity, is ampliﬁed in about 5–10% of breast cancers but
20–25% of the basal breast cancers. This enzyme removes
dimethyl and trimethyl groups from histone H-3 lysine-
9 and 36 residues which results in altered transcriptional
patterns in these cells. Inactivation of gene functions by
deletion or other mechanisms commonly occurs in (1)
PTEN in breast, ovarian, and endometrial cancers, and (2)
p53 in HER2/neu positive breast cancers, triple negative
breast cancers, and BRCA-associated breast and ovarian
cancers. PI3K ampliﬁcations and activating mutations are
common in breast and endometrial cancers [31, 32]a n dR a s
activating mutations are common in endometrial cancers.
Several genes such as AKT and STAT3 are often expressed at
high activities in all of these cancers but without detectable
ampliﬁcations of those genes. Epigenetic alterations, such as
methylation of cytosine residues in CpG dinucleotides, can
bring about the inactivation of genes (p16 gene in breast
cancers) while mismatch repair defects have been observed
to enhance the mutation rate of many genes in endometrial
cancers. In addition to those somatic mutations discussed
here, a large number of mutations in many oncogenes and
tumor suppressor genes have been observed at lower rates in
women’s cancers.
Large copy number variations in genetic loci from
tumor tissues have been observed using ﬂuorescent in situ
hybridization (FISH), comparative genomic hybridization
(CGH), and a reduced heterozygosity of single nucleotide
polymorphisms over large regions of a chromosome. This
type of genomic instability has been observed at many loci in
allchromosomesinsomebreasttumors.Otherbreasttumors
demonstrate little or no genomic instability (below the level
of detection). As a generalization those individuals who
have tumors that demonstrate very high levels of genomic
instability have a poorer prognosis [33]. While some loci are
repeatedly ampliﬁed, as occurs in Her2 overexpressing breast
cancers,ordeleted,aswithPTENinendometrialcancers,the
heterogeneity of mutations in women’s cancers is striking.
There are many mutational paths to initiate and propagate
at u m o r .
Notablyhowever,somaticmutationsoftenoccuringenes
where germline mutations in those same genes are the
etiologic factors in cancer susceptibility syndromes. Alter-
natively, somatic mutations occur in other genes involved
in regulatory aspects of those vital pathways. Despite the
number of mutational pathways to initiate and propagate
tumors, several speciﬁc genomic alterations are associated
with particular breast cancer phenotypes. These phenotypes
are manifested in their molecular proﬁle, biology, and
prognosis. Patterns of transcriptional proﬁles obtained from
breast tumors have permitted a fairly reproducible classiﬁ-
cation of breast cancers that are derived from diﬀerent cell
types or have evolved under the inﬂuence of diﬀerent gene
expression patterns [34–38]. These diﬀerent transcriptional
patterns correlate well with critical diagnostic criteria (ER+,
PR+, HER-2/neu+, triple negative, BRCA1) that guide both
diagnosis and treatment protocols for these types of breast
cancers. The classiﬁcation also correlates well with some
mutations such as p53, but other causal mutations such
as cyclin D and WIP1 ampliﬁcations, PI3K and STAT3
activations need to be explored. Classiﬁcation based upon
transcriptional proﬁles also associates well with several
clinical parameters. For example, luminal A cancers are
hormone receptor positive, are diagnosed primarily in older
women, are low grade with low proliferative index, and have
mainly wildtype p53 [35, 38]. Luminal B cancers also tend
to retain wildtype p53 but have reduced or absent expression
of progesterone receptor and are more likely to recur than
luminal A cancers [35, 36, 38]. In contrast to luminal
tumors, basal cancers are hormone receptor negative and
Her2 negative, are more likely to be diagnosed in young, pre-
menopausal women, are high grade with high proliferative
index, and are associated with higher risk of recurrence [35–
38]. Her2-ampliﬁed breast cancers, regardless of hormone
receptor status, are of higher grade and proliferative index,
have worse prognosis with higher recurrences in ﬁrst ﬁve
years after diagnosis, and commonly have p53 mutations
[35, 36]. Like basal tumors, BRCA1-associated breast cancers
predominantly occur in young, premenopausal women, are
primarily hormone receptor negative, and the most likely to
carry p53 mutations [34]. Unfortunately this type of detail
and analysis does not yet exist for ovarian and endometrial
cancers.
Thus, it is now clear that there are at least ﬁve types
of breast cancer with characteristic transcriptional proﬁles
that can harbor some subset of mutations that drive these
cancers [39]. Importantly, each type of breast cancer calls for
diﬀerent treatment protocols and often results in diﬀerent4 Journal of Oncology
outcomes. We have only partially established the critical
mutational patterns in each type of breast cancer and we
have only begun to extend this type of analysis to other
women’s cancers. However, it is apparent that breast cancer
heterogeneityreﬂectsunderlyinggenomicalterationsleading
to diﬀerent biology and phenotypes.
3. SingleNucleotidePolymorphisms(SNPs)and
Their Phenotypes
Inherited mutations in genes involved in DNA repair pro-
cesses(BRCA1,BRCA2),cellcyclecheckpointsandapoptosis
(p53 , Rb), and gene products that regulate critical pathways
(PTEN) clearly play a central role in predetermining the
initiation of cancers, often with an incomplete penetrance.
Polymorphic alleles in many additional genes, often in these
same signal transduction pathways, can also contribute,
albeit in a smaller quantitative fashion, to the origins of
a cancer, the propagation of a cancer, and the treatment
responses of a cancer. By deﬁnition a mutation in a gene
occurs rarely in a population (below 1% of the population
under study) whilea polymorphism occursmore commonly.
Because these polymorphic alleles can act cooperatively
and many genes in the same signal transduction pathway
can show epistatic relationships, single nucleotide polymor-
phisms(SNPs)andcopynumbervariations(CNVs)canhave
observableimpactupontheincidenceofacancerinadeﬁned
population, the age of onset of a cancer, the response to
treatment, the frequency of relapse, and the overall survival
of a patient population. Thus in addition to inherited
mutations,SNPsandCNVsinapopulationprovideagenetic
background that can inﬂuence the cancer cells harboring
the inherited and somatic mutations that arise and cause a
tumor. The phenotypes observed in people with inherited
mutations in cancer causing genes are an increased incidence
of cancers in a family or population and an earlier age of
onset of a cancer than observed in the total population.
Mutations in the p53 gene show this pattern and in addition
multiple independent cancers in the same individual can be
observed [3, 12]. Inherited mutations also often produce
a limited set or tissue type of cancer such as BRCA1 or
BRCA2 withbreastand ovarian tumors [3].Itis thought that
the BRCA1 and BRCA2 proteins function in many tissues
to repair DNA damage, so the limited cancer causation
to breast and ovary remains a mystery. Indeed all of the
tumor suppressor genes demonstrate a tissue preference in
the tumors they cause when they function as inherited alleles
butsomaticmutationsinthosesamegenesareoftenfoundin
a much wider group of cancers of diﬀerent tissues [40]. SNPs
and CNVs will likely also have limited tissue impact upon
cancers and like inherited mutations, functioning through-
out development and life, can have cumulative impact over
a lifetime.
The possible role of a SNP or an CNV in cancer is
usually demonstrated by an association study correlating
the presence of an “at-risk” allele with the incidence of
a cancer or a related phenotype. This is fundamentally a
statistical argument that provides correlation, not causality.
The situation gets better if the at-risk allele can be shown,
in vitro or in vivo, to have a diﬀerent level or activity that
could lead to the population wide phenotype. Examples of
these correlations are now being demonstrated for results
from GWAS and are taking into account tumor subtypes
[41]. Thus molecular and cellular studies can provide an
important rational for the population study results. In some
cases it may also be possible to model the at-risk allele
in another genetic system, such as a mouse carrying the
alternatehumanallelesintheorthologousgeneofthemouse.
One would then explore the phenotypes observed in humans
using such a mouse model. In this way it may be possible to
move from correlation to causality. In the process of these
studies one may learn about the details of the properties of
an SNP or CNV that enlightens the population studies. A
very good example of this is an SNP, SNP309, in the ﬁrst
intron of the MDM2 gene in humans. The MDM2 protein
is a ubiquitin ligase which negatively regulates p53 levels in
a cell by polyubiquitination of the p53 protein followed by
its degradation. Thus MDM2 levels and activity in a cell
regulatethep53proteinlevelsinacell.SNP309intheMDM2
gene comes in two forms, a G-allele and a T-allele. The ﬁrst
intron of the MDM2 gene contains sites for transcription
factors that regulate the levels of the MDM2 mRNA. The
G-allele binds a transcription factor, Sp-1, better than the
T-allele [42]. Ten base pairs away from this Sp-1 site is an
ER binding site and the Sp-1 and ER transcription factors
can interact so that the highest levels of MDM2 mRNA and
protein are produced in cells that are G/G homozygotes and
ER+ and exposed to estrogen as shown in breast cancer
cells in culture. Indeed the association of the G-allele of
SNP 309 with an early age of onset of a cancer is most
commonly observed in premenopausal women with ER+
tumors [43]. Thus if one analyzes all women with breast
cancers for an association with the presence of the “at-
risk” allele of this SNP the statistical test for an association
commonly fails. Only when the association is tested with
premenopausal females with ER+ tumors can a clear associ-
ation be found. This is a good example of understanding the
biology and genetics before one undertakes large association
studies.
The human genome of any individual contains about
threemillionSNPsthatdistinguishthatpersonfromanother.
In the population of humans there are an estimated ﬁfty
million SNPs. Most of these diﬀerences have no detectable
phenotype. Because of this, large genome wide scans
(GWAS) of SNPs now employ a million SNPs to test for an
association with a disease [44]. This is clearly an exercise
in multiple hypothesis testing and so one requires very
large populations of cases (and controls) and a statistical
s i g n i ﬁ c a n c e( at y p e1e r r o rr a t e )t h a tp r o v i d e saP =
10
−7 value. Even then the number of false positives can
be large and so repeated independent studies are required
to reﬁne the truly signiﬁcant associations. This is in part
why many SNP associations with cancers have been so
poorly reproducible. Small study populations will often give
lots of false positives not observed in independent repeat
studies. In case-control studies where one is examining
the diﬀerent allele frequencies in a case and a controlJournal of Oncology 5
group there is presently no mathematical test to prove that
these two populations are equivalent. Allele frequencies can
diﬀer in racial groups or other populations and while it
is easy to control for some parameters we do not know
all of the variables. In spite of these diﬃculties several
recent publications employing GWAS approaches with large
populations have been reported for associations with breast
cancers, colorectal cancers, lung cancers, melanomas and
prostate cancers [17, 22, 24, 25, 45–51].
Ad i ﬀerent approach to uncovering active SNPs with
associations to cancers is to examine a small number of
candidate genes for the presence of SNPs that impact upon a
phenotype. The criticism of this approach is that novel genes
and SNPs that impact upon a cancer will not be discovered
by this approach. Rather it is a chance to delve deeper into
the diversity and properties of a gene, its protein and its
phenotypes in a population. The most likely candidate genes
that have functional SNPs are the ones that have mutations
in some cancers or provide an inherited basis for cancer
when they are mutated. Because SNPs are expected to be
less deleterious than a mutation which inactivates or fully
activatesafunction,itishelpfultolookforcandidateSNPsin
genesthatdemonstratehaploinsuﬃciency.Thisencompasses
those genes that have a cancer-related phenotype when an
individual has only one wild type allele, and presumably
half the activity and level of a protein. Interestingly the
p53 gene, MDM2 gene, and the MDM4 gene (a second
negative regulator of p53 that acts upon MDM2) are all
haploinsuﬃcient genes in mice and p53 is haploinsuﬃcient
in humans (there is presently no test for MDM2 or MDM4
haploinsuﬃciency in humans) [52, 53]. These three proteins
make up the core of p53 regulatory activities in a cell (see
Figure 1) .T h e r ei sag r e a td e a lo fe v i d e n c ed e m o n s t r a t i n g
that the levels and/or activities of these proteins in a cell are
tightly controlled by extensive feedback loops and that small
changes in these proteins have phenotypes that are readily
observed.
AnotherwaytolookforSNPsthathavebiologicalactivity
is to examine whether a mutant allele or a polymorphic allele
is under negative or positive selection in a population. If that
is the case then that allele must have a biological activity that
impacts upon the organism. There are now a growing num-
ber of methods to look for regions of a genetic locus under
positive or negative selection. Selection pressures in humans
commonly result from genes that contribute to resistance to
infectious diseases (about 20% of human cancers are caused
by or associated with viruses), optimal use of nutritional
opportunities(theIGF-PI3K-PTEN-mTORpathwayshelpto
regulate this), or the highest levels of fecundity, leaving more
oﬀspring in a population (the p53 pathway can participate
in this and is discussed below). Employing information
theory-entropy based methods Atwal et al. have suggested
that some alleles of MDM2 and MDM4 are under positive
selective pressures in Caucasian populations [54, 55]. Based
on identiﬁcation of selected loci in MDM4, studies have now
demonstrated associations between MDM4 SNP loci with
risk of breast and ovarian cancers as well as age of onset
of ovarian cancers and hormone receptor negative breast
cancers [55, 56].
There is also evidence that an allele in the coding region
of the p53 protein may also be under positive selective
pressure in Caucasian populations. This SNP at codon 72
in the p53 protein (out of 393 amino acids) either encodes
an arginine (Arg) or a proline (Pro) residue. The Pro-
allele is the ancestral form and Africans near the equator
have very high levels of the Pro-allele. As populations
move to northern latitudes in Europe (Caucasians) and in
Asia (Asians) there is an increasing frequency of the Arg-
allele reaching 75–85% in Scandinavia. One explanation
for this distribution comes from the observation that
p53 induces the synthesis of pro-opiomelanocortin which
regulates the tanning response. This could be thought of
as a protective mechanism for light-skinned populations
or helping to protect individuals of lighter skin color
which was developed to enhance the production of vitamin
D in northern climates. In a recent study in China, a
correlation was found that implicates both temperature
and ultra-violet light sources as the driving forces upon
selection of the p53 Arg/Pro and SNP309 polymorphisms
[57].
There is a growing body of evidence that the newly
formed and selected Arg-allele in Caucasian and Asian
populationshasquitediﬀerentpropertiesthenthePro-allele.
Cells in culture with the Arg-allele transcribe several pro-
apoptotic genes at higher rates than the same cell lines with
Pro-alleles. Several studies have demonstrated that cells with
the Arg-allele undergo higher frequencies of apoptosis than
the same cells with Pro-alleles. A deletion of the p53 protein
proline rich domain, in which the Arg/Pro polymorphism
resides, reduces the eﬃciency of apoptosis by that mutant
p53 protein. These studies demonstrate at the cellular and
molecular level that functional diﬀerences exist between
these two alleles of the p53 gene [58–61].
Perhaps the best explanation for the selection of the p53
Arg allele in Caucasian populations is the observation that
the cytokine leukemia inhibitory factor (LIF) is regulated
at the transcriptional level by p53 and two times more
LIF is produced in cells by the Arg-allele than the Pro-
allele of p53 [62]. p53-mediated production of LIF in
the uterus is required for implantation of mouse embryos
after fertilization (LIF is also produced in humans for
implantation) and so both p53 and LIF are required for
high levels of fecundity [63]. Interestingly, the frequency
of the p53 Pro-allele is quite enriched in women who
are at an in vitro fertilization clinic and demonstrate
lower levels of implantation of fertilized eggs [62]. This
observation may explain the selective pressures on these
alleles in Caucasians. Obviously there are not similar fertility
diﬃculties in Africans with the Pro-allele, suggesting that
the genetic background (other alleles in genes in the p53
pathway) is an important factor for this phenotype. Poor
fertility was observed in p53 knockout mice and varied in
diﬀerent genetic backgrounds [63]. Some of the compen-
sating MDM2 and MDM4 alleles are also under selection
pressures in Caucasian populations. It has been these types
of studies that have identiﬁed functional SNPs that can now
be tested for their activities and associations with speciﬁc
cancers.6 Journal of Oncology
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4. The p53 Pathway and Cancer Prevention
The p53 protein and its signal transduction pathway respond
to a wide variety of stresses and act as a ﬁdelity check
point preventing mistakes leading to high mutation rates.
Cellular stresses such as DNA damage, telomere shortening,
hypoxia, nutrient deprivation, an interruption of ribosome
biogenesis, errors in proper mitotic spindle functions, or
even the mutational activation of selected oncogenes (myc,
Ras) can activate the p53 protein so that it becomes an
eﬃcient transcription factor for selected genes. A wide vari-
ety of protein kinases, histone methylases, ubiquitin ligases,
and so forth participate in detecting these stress signals and
modifying the p53, MDM2, or MDM4 proteins. This results
in shutting down the MDM2/4 negative regulation of p53,
an increased half-life, and an increased concentration of the
p53 protein in the cell (Figure 1). Higher levels of a modiﬁed
p53proteinthengiverisetoatranscriptionalresponseofp53
regulated genes. The most common outcomes of this signal
transduction pathway are apoptosis, cellular senescence, or
cell cycle arrest. Because these stresses upon a cell can cause
a very high error rate in both DNA replication and cell
division, p53 blocks progression through the cell cycle or
eliminates clones that contain mutational events. In this
way p53 acts as a tumor suppressor gene over a lifetime of
stressful events. The presence of only one wild type p53 allele
inmiceorhumans(Li-Fraumenisyndrome)leadstoanearly
onset of tumors compared to the wild type population and
often leads to multiple independent tumors in an individual
with almost a one hundred percent penetrance [64, 65].
Four independent studies have now shown that the G-
allele (at-risk allele) of SNP309 in the MDM2 gene, which
raises the levels of this mRNA and protein inhibiting p53
activity, lowers the age of onset of tumors and increases the
number of independent tumors observed in individuals with
Li-Fraumeni syndrome [42, 66–68]. Those individuals with
Li-Fraumeni syndrome who do not have a p53 mutation
(patientswithahighfrequencyoftumorsduetoanunrelated
mutation) are not aﬀected by the SNP309 G-allele demon-
strating the speciﬁcity and epistatic relationship between
MDM2 and p53. Li-Fraumeni patients with a p53 mutation
also have more rapid telomere erosion, demonstrating the
role of p53 and SNP309 in this process [67]. It is well known
that p53 senses the loss of telemetric DNA and will stop cell
division or cause cellular apoptosis. One study examining
both the p53 Arg/Pro and SNP309 polymorphisms suggested
that the p53 Pro-allele can have an impact upon the age of
onset of cancers (earlier) and survival (poorer) in patients
with Li-Fraumeni syndrome and SNP309 can make the
situation worse, but the number of patients with both geno-
types was too small to obtain a statistically conﬁdent result
[68].
5.SNPsinthep53Pathway Associatedwith
BreastandOvarianCancers
The literature examining the association of SNPs in genes in
the p53 pathway is fraught with contradictions. Undoubt-
edly, this comes about for several reasons. First, studies
involving small population sizes do not necessarily provide
adequate statistical power. Second, studies may fail to
stratify populations into groups that reﬂect the biology and
clinical impacts of a cancer. For example, MDM2 SNP309,
which acts preferentially in premenopausal females with
ER+ tumors, is a smaller group in the total cohort. Third,
there is a failure to understand that SNPs in diﬀerent
genes may have very diﬀerent phenotypes in the context
of a cancer (tissue speciﬁcity, the age of onset phenotype,
etc.). Finally, there is a tendency to make comparisons of
cases and controls that are not biologically or genetically
equivalent.Journal of Oncology 7
At present, the structure of many association studies
leads to false positives and negatives as well as uncovering
an occasional functional SNP. For example, a very large
population of women with breast cancer was analyzed in
a GWAS but the patients were not stratiﬁed by ER status
or for any of the clear diﬀerences between diﬀerent types
of breast cancers [22]. Clearly, this will dilute any signal
that comes from just one of these cancer types. In addition,
when SNPs in tumor suppressor genes or oncogenes are
under study it may be the case that a mutation in that
gene will eliminate the SNP from being identiﬁed or all
SNPs in genes epistatic to the mutated gene may no longer
score in the association study. Because of these diﬃculties
we must rely upon the independent replication of results
as well as a functional explanation for how an SNP is
acting to uncover an association. In a formal large meta-
analysis of published results from the literaturevan Heemst
et al. [69] studied the impact of p53 Pro/Pro and Arg/Arg
polymorphisms upon the frequency of developing cancers
and upon the longevity of the population under study. They
found that individuals with a Pro/Pro genotype had an
increased risk of developing a cancer over their lifetimes
when compared to individuals with an Arg/Arg genotype.
In a prospective study of individuals 85 years and older,
carried out with 1226 people over a ten-year period, they
found that people with the Pro/Pro genotype had a 2.45
increased proportional mortality from cancer (P = .007).
But this group also showed a longer longevity (a 41%
increased survival in the population, P = .032). One
interpretation of this result is that the Arg/Arg genotype
has a higher apoptotic rate in response to stress and so
protects against cancer better, but also kills stem cells more
eﬃciently over a lifetime, reducing longevity [69]. This
suggests that studying older patients may reveal a phenotype
in this p53 SNP because it acts over a lifetime to protect
the host from stresses. By the same token, older mice show
declines in p53 activities with age and this lower level of
p53 responses could uncover a phenotype at older ages that
is too robust to measure in younger groups [70]. If this
interpretation is correct one can see why the p53 Arg/Pro
SNP has given rise to such contradictory responses when
the ages of the case and control groups are not taken into
account.
Similarly, studies with MDM2 SNP309 have produced
contradictory associations with cancers. Some of this has to
dowithmixingbothmalesandfemalesintothecohortunder
study (SNP309 is regulated by the ER), some of this has to
do with a failure to separate ER+ and ER− tumors in the
analysis, and some studies just choose the wrong phenotype
or cohort to measure. For example, the observation that
the G-allele (the at-risk allele) of SNP309 is associated with
an earlier age of onset in a variety of cancers has now
been reproduced by many independent groups employing
soft tissue sarcomas [43], lymphomas [43], leukemia [71],
melanomas [72], head neck [73] and oral squamous cell
carcinomas [74], gastric cancer [75], colon cancers [76, 77],
lung cancers [78–80], endometrial cancer [81, 82], bladder
cancers [83, 84], glioblastoma [85], neuroblastoma [86], and
both breast cancers [43] and ovarian [87] cancers. In a study
of lung cancers, Lind and her colleagues [78] found that
G/G homozygotes had a 1.62 odds ratio of developing cancer
compared with T/T homozygotes. When only females in the
study were considered the G/G to T/T odds ratio was 4.06.
This is the same result observed in an independent study
with large diﬀuse B-cell lymphomas where the G-allele of
SNP309 was associated with cancer only in premenopausal
females and not in postmenopausal females nor in men
[43].
In a third recent study of melanomas, a similar associ-
ation was found only in premenopausal females [72]. This
pattern suggests that active estrogen receptors are present in
a large number of tumors and can aﬀect the outcome of the
disease. This set of genetic observations opens up possible
new routes for therapy with these tumors. In another large
study with lung cancer patients carried out in China by
Zhang et al. [80] they demonstrated an odds ratio of 1.83
for the G/G over T/T alleles and a 1.47 fold odds ratio for the
p53 Pro/Pro over Arg/Arg individuals. Those patients who
were G/G and Pro/Pro had an odds ratio of 4.36; whereas
those smokers (a mutagenic stress that activates p53) who
werePro/Pro,G/Ghadanoddsratioof10.41.Understanding
the biology of the signal transduction pathway can permit
one to study the relevant variables. Often combinations of
SNPs that have an epistatic relationship can provide much
more signiﬁcant results.
Recently, biologically functional SNPs were detected in
the MDM4 gene that appear to be under evolutionary
selection pressures and have an impact upon fecundity
in females at an IVF clinic [62, 63]. Association studies
employing ﬁve diﬀerent patient populations have indicated
that selected alleles of these SNPs confer an increased risk
for or early onset of breast cancers and ovarian cancers
[55, 56]. The ethnic backgrounds of the cohorts under
study made a diﬀerence in the ability to detect these
associations so that once again a genetic background of
other SNPs that reside in other genes in the same pathway
could play an important role. The minor alleles of these
same MDM4 SNPs demonstrated a clear enrichment in
their frequencies in women at an IVF clinic who had
diﬃculties with implantation of embryos. These diverse
phenotypes suggest a functional consequence of these SNPs
that can be selected for or against over recent (Caucasian
and Asian) times of human evolution. It will be important
to observe replications of these data in a wide variety of
cancers.
Because many of the cancer treatments result in DNA
damage and other stresses to a cell, the response (as
determined by a combination of SNPs) to treatment and
long-term survival could depend upon the combination
of alleles in the p53 pathway SNPs. To test this notion
association studies will have to assemble large groups of
individuals who have experienced a deﬁned cancer and
treatment and record the outcomes over many years. Such
cohorts are more diﬃcult to assemble but are an important
part of this eﬀort. Characterizing the patient and the tumor
genome prior to the selection of treatments is a growing
concernand wouldbe aided by the use of validated SNPs and
mutations.8 Journal of Oncology
6. LimitationswithSNP Studies
The success of these studies has been in part due to the use
of large study samples (usually based around multicenter
consortia) and replication data sets that have been designed
into the gene discovery algorithm. Although this approach
maximizes the identiﬁcation of possible genes involved in
contributing to breast cancers, these studies often give rise to
anumberoffalsepositiveﬁndingsduetomultiplehypothesis
testing with a very large number of SNPs in the GWAS
scans. In addition, the GWAS approach tends to optimize
the discovery of genes with statistically signiﬁcant marginal
eﬀects. Therefore, it may miss signiﬁcant genes. First, genes
may not be detected whose eﬀects are not signiﬁcant on
the margin but are signiﬁcant in conjunction with other
genes or exposures. Second, genes may not be identiﬁed if
there is substantial genetic heterogeneity among cases, such
that the proportion of individuals in the population whose
disease is caused by a gene is so small that its eﬀect is
“washedout”inthetotalsample.Third,GWASstendtofavor
largenumbersoverepidemiologicallyrigorousstudydesigns.
Although large samples are clearly required to detect small
eﬀects, and replication/validation of initial results maximizes
the chances that reported associations are true positives,
it is possible that unmeasured biases due to study design
limitations may have resulted in high false negatives.
Likewise, meta-analyses, used to critically evaluate and
statistically combine studies, have been performed for
MDM2 SNP309. However, a caveat to such an analysis is that
the studies are comparable. Population-speciﬁc eﬀects and
SNPfunctionalityinindependentracialgeneticbackgrounds
may exist and limit the ability to combine heterogeneous
studygroups.Toemphasizethis,Shietal.describeacausative
selection of MDM2 SNP309 and p53 Arg72 associated with
environmental stresses, that is, cold winter temperatures and
UV intensity, wherein the two SNPs are not coselected [57].
This is further supported by two publications describing
population-speciﬁc diﬀerences between African-Americans,
Caucasians, and Caucasians of Ashkenazi Jewish descent for
both MDM2 SNP309 and MDM4 haplotypes [54, 55]. A
combined analysis for SNP309 was presented in Wilkening
et al. [88]. Data from eleven breast cancer studies, ﬁve
colorectal cancer studies, or seven lung cancer studies were
each combined for a ﬁxed meta-analysis. Based on their
analysis, they concluded that the SNP309 variant did not
have an impact on risk or colorectal cancers, but did exhibit
increased risk in the homozygous state for lung cancer.
They concluded that SNP309 alone has little eﬀect on the
risk of common cancers. In reviewing criteria of studies
withintheanalysis,thereissigniﬁcantheterogeneitybetween
study groups. Other studies have also previously concluded
that the eﬀects of SNP309 are evident in women but not
in men and in hormone receptor-positive breast cancers
[43]. Most studies do not diﬀerentiate between gender or
hormone receptor positive diseases, both of which may
dilute any eﬀects. In contrast to the conclusions made by
Wilkening et al. [88], those of Hu et al. [89] are that the
homozygous variant is associated with increased risk of all
types of tumors where tumor type and ethnicity contributed
to substantial heterogeneity. The latter publication by Hu
et al. [89] describes in detail methods for identifying
appropriate studies, data extraction and analysis. The major-
ity of publications fail to reduce heterogeneity in their
populations based on molecular markers, gender, and degree
of disease heterogeneity. Therefore, a meta-analysis would
be limited by these factors and should be interpreted with
caution.
The majority of useful and reproducible reports involv-
ing SNP associations with breast, ovarian, and endometrial
cancers have occurred in the context of candidate gene
studies. These studies typically identify loci that are hypoth-
esized to contain genetic variants that may be associated
with disease risk. Using this approach, a number of putative
susceptibility genes have been identiﬁed for these tumor
sites that have been validated. Furthermore, candidate gene
s t u d i e sh a v et e n d e dt oh a v eu s e dm o r er i g o r o u ss t u d y
designs, collected useful epidemiological and confounder
data, and have detailed information that may deﬁne etiologi-
cally heterogeneous groups of individuals that may provide
a setting in which genes that are not easily detectable in
the usual GWAS setting may be found. This comes about
b e c a u s ew eh a v eag r e a td e a lo fi n f o r m a t i o na b o u tt h o s e
genes already known to play a role in cancer causation that
modiﬁes the questions we ask and the associations we look
for in a study. It appears that both the GWAS algorithm and
the candidate gene algorithm may have value in identifying
susceptibilitygenes,andthesegenesmaybediﬀerentbecause
of the strengths and weaknesses of each approach.
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